Inhibitory effects of lycopene on HMGB1-mediated pro-inflammatory responses in both cellular and animal models

Food and Chemical Toxicology

Volumn 50, Issue 6, 2012, Pages 1826-1833

  Lee, Wonhwa ^a,b   Ku, Sae Kwang ^c   Bae, Jae Woan ^d   Bae, Jong Sup ^a  

^a Kyungpook National University   (South Korea)

^b Kyungpook National University School of Medicine   (South Korea)

^c Daegu Haany University   (South Korea)

^d Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

Author keywords

HMGB1; Inflammation; Lycopene; Vascular disease

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HIGH MOBILITY GROUP B1 PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; LIPOPOLYSACCHARIDE; LYCOPENE; PHOSPHOLIPASE A2 GROUP II; PHOSPHOLIPASE A2 GROUP IIA; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD VESSEL PERMEABILITY; CELL SURFACE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VIVO STUDY; LEUKOCYTE ADHERENCE; LEUKOCYTE MIGRATION; MONOCYTE; MOUSE; NONHUMAN; PERITONEAL CAVITY; PROTEIN EXPRESSION; PROTEIN SECRETION; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BLOTTING, WESTERN; CAROTENOIDS; CELL ADHESION; CELL MEMBRANE PERMEABILITY; CELL MOVEMENT; CELL SURVIVAL; CELLS, CULTURED; DOWN-REGULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GROUP V PHOSPHOLIPASES A2; HMGB1 PROTEIN; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; INFLAMMATION; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED ICR; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, CELL SURFACE; RECEPTORS, IMMUNOLOGIC; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA; LYCOPERSICON ESCULENTUM; MUS;

EID: 84860155576     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2012.03.003     Document Type: Article

References (47)

1. Abraham E., Arcaroli J., Carmody A., Wang H., Tracey K.J. HMG-1 as a mediator of acute lung inflammation. J. Immunol. 2000, 165:2950-2954.
2. Andersson U., Wang H., Palmblad K., Aveberger A.C., Bloom O., Erlandsson-Harris H., Janson A., Kokkola R., Zhang M., Yang H., Tracey K.J. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J. Exp. Med. 2000, 192:565-570.
3. Bae J.S., Kim Y.U., Park M.K., Rezaie A.R. Concentration dependent dual effect of thrombin in endothelial cells via Par-1 and Pi3 Kinase. J. Cell Physiol. 2009, 219:744-751.
4. Bae J.W., Bae J.S. Barrier protective effects of lycopene in human endothelial cells. Inflamm. Res. 2011, 60:751-758.
5. Bonaldi T., Talamo F., Scaffidi P., Ferrera D., Porto A., Bachi A., Rubartelli A., Agresti A., Bianchi M.E. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J. 2003, 22:5551-5560.
6. Boonyaratanakornkit V., Melvin V., Prendergast P., Altmann M., Ronfani L., Bianchi M.E., Taraseviciene L., Nordeen S.K., Allegretto E.A., Edwards D.P. High-mobility group chromatin proteins 1 and 2 functionally interact with steroid hormone receptors to enhance their DNA binding in vitro and transcriptional activity in mammalian cells. Mol. Cell Biol. 1998, 18:4471-4487.
7. Britton G. Structure and properties of carotenoids in relation to function. FASEB J. 1995, 9:1551-1558.
8. Bustin M., Reeves R. High-mobility-group chromosomal proteins: architectural components that facilitate chromatin function. Prog. Nucl. Acid Res. Mol. Biol. 1996, 54:35-100.
9. Chen X., Oppenheim J., Howard O.M. Shikonin, a component of antiinflammatory Chinese herbal medicine, selectively blocks chemokine binding to CC chemokine receptor-1. Int. Immunopharmacol. 2001, 1:229-236.
10. Dudek S.M., Garcia J.G. Cytoskeletal regulation of pulmonary vascular permeability. J. Appl. Physiol. 2001, 91:1487-1500.
11. El Gazzar M. HMGB1 modulates inflammatory responses in LPS-activated macrophages. Inflamm. Res. 2007, 56:162-167.
12. Fisher M. Injuries to the vascular endothelium: vascular wall and endothelial dysfunction. Rev. Neurol. Dis. 2008, 5(Suppl 1):S4-11.
13. Fiuza C., Bustin M., Talwar S., Tropea M., Gerstenberger E., Shelhamer J.H., Suffredini A.F. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 2003, 101:2652-2660.
14. Gaugler M.H. A unifying system: does the vascular endothelium have a role to play in multi-organ failure following radiation exposure?. BJR Suppl. 2005, 27:100-105.
15. Goodwin G.H., Sanders C., Johns E.W. A new group of chromatin-associated proteins with a high content of acidic and basic amino acids. Eur. J. Biochem. 1973, 38:14-19.
16. Hansson G.K., Libby P. The immune response in atherosclerosis: a double-edged sword. Nat. Rev. Immunol. 2006, 6:508-519.
17. Heber D., Lu Q.Y. Overview of mechanisms of action of lycopene. Exp. Biol. Med. (Maywood) 2002, 227:920-923.
18. Hori O., Brett J., Slattery T., Cao R., Zhang J., Chen J.X., Nagashima M., Lundh E.R., Vijay S., Nitecki D., et al. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J. Biol. Chem. 1995, 270:25752-25761.
19. Huttunen H.J., Fages C., Rauvala H. Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J. Biol. Chem. 1999, 274:19919-19924.
20. Jaulmes A., Thierry S., Janvier B., Raymondjean M., Marechal V. Activation of sPLA2-IIA and PGE2 production by high mobility group protein B1 in vascular smooth muscle cells sensitized by IL-1beta. FASEB J. 2006, 20:1727-1729.
21. Kim T.H., Ku S.K., Lee I.C., Bae J.S. Anti-inflammatory effects of kaempferol-3-O-sophoroside in human endothelial cells. Inflamm. Res. 2012, 61:217-224.
22. Klipstein-Grobusch K., Launer L.J., Geleijnse J.M., Boeing H., Hofman A., Witteman J.C. Serum carotenoids and atherosclerosis. The Rotterdam Study. Atherosclerosis 2000, 148:49-56.
23. Kohlmeier L., Kark J.D., Gomez-Gracia E., Martin B.C., Steck S.E., Kardinaal A.F., Ringstad J., Thamm M., Masaev V., Riemersma R., Martin-Moreno J.M., Huttunen J.K., Kok F.J. Lycopene and myocardial infarction risk in the EURAMIC Study. Am. J. Epidemiol. 1997, 146:618-626.
24. Luscher, T.F., Barton, M., 1997. Biology of the endothelium. Clin Cardiol 20, II-3-10.
25. Marui N., Offermann M.K., Swerlick R., Kunsch C., Rosen C.A., Ahmad M., Alexander R.W., Medford R.M. Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. J. Clin. Invest. 1993, 92:1866-1874.
26. Menschikowski M., Hagelgans A., Siegert G. Secretory phospholipase A2 of group IIA: is it an offensive or a defensive player during atherosclerosis and other inflammatory diseases?. Prostaglandins Other Lipid Mediat. 2006, 79:1-33.
27. Mesters R.M., Helterbrand J., Utterback B.G., Yan B., Chao Y.B., Fernandez J.A., Griffin J.H., Hartman D.L. Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications. Crit. Care Med. 2000, 28:2209-2216.
28. Mullins G.E., Sunden-Cullberg J., Johansson A.S., Rouhiainen A., Erlandsson-Harris H., Yang H., Tracey K.J., Rauvala H., Palmblad J., Andersson J., Treutiger C.J. Activation of human umbilical vein endothelial cells leads to relocation and release of high-mobility group box chromosomal protein 1. Scand. J. Immunol. 2004, 60:566-573.
29. Osterud B., Bjorklid E. Role of monocytes in atherogenesis. Physiol. Rev. 2003, 83:1069-1112.
30. Palumbo R., Sampaolesi M., De Marchis F., Tonlorenzi R., Colombetti S., Mondino A., Cossu G., Bianchi M.E. Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation. J. Cell Biol. 2004, 164:441-449.
31. Park J.S., Svetkauskaite D., He Q., Kim J.Y., Strassheim D., Ishizaka A., Abraham E. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J. Biol. Chem. 2004, 279:7370-7377.
32. Porto A., Palumbo R., Pieroni M., Aprigliano G., Chiesa R., Sanvito F., Maseri A., Bianchi M.E. Smooth muscle cells in human atherosclerotic plaques secrete and proliferate in response to high mobility group box 1 protein. FASEB J. 2006, 20:2565-2566.
33. Riedemann N.C., Ward P.A. Anti-inflammatory strategies for the treatment of sepsis. Expert Opin. Biol Ther. 2003, 3:339-350.
34. Rissanen T., Voutilainen S., Nyyssonen K., Salonen J.T. Lycopene, atherosclerosis, and coronary heart disease. Exp. Biol. Med. (Maywood) 2002, 227:900-907.
35. Rissanen T.H., Voutilainen S., Nyyssonen K., Salonen R., Kaplan G.A., Salonen J.T. Serum lycopene concentrations and carotid atherosclerosis: the Kuopio Ischaemic Heart Disease Risk Factor Study. Am. J. Clin. Nutr. 2003, 77:133-138.
36. Rouhiainen A., Kuja-Panula J., Wilkman E., Pakkanen J., Stenfors J., Tuominen R.K., Lepantalo M., Carpen O., Parkkinen J., Rauvala H. Regulation of monocyte migration by amphoterin (HMGB1). Blood 2004, 104:1174-1182.
37. Sabroe I., Dower S.K., Whyte M.K. The role of Toll-like receptors in the regulation of neutrophil migration, activation, and apoptosis. Clin. Infect. Dis. 2005, 41(Suppl 7):S421-426.
38. Sama A.E., D'Amore J., Ward M.F., Chen G., Wang H. Bench to bedside: HMGB1-a novel proinflammatory cytokine and potential therapeutic target for septic patients in the emergency department. Acad. Emerg. Med. 2004, 11:867-873.
39. Sappington P.L., Yang R., Yang H., Tracey K.J., Delude R.L., Fink M.P. HMGB1 B box increases the permeability of Caco-2 enterocytic monolayers and impairs intestinal barrier function in mice. Gastroenterology 2002, 123:790-802.
40. Shimaoka M., Park E.J. Advances in understanding sepsis. Eur. J. Anaesthesiol. Suppl. 2008, 42:146-153.
41. Teiten M.H., Eifes S., Dicato M., Diederich M. Curcumin-the paradigm of a multi-target natural compound with applications in cancer prevention and treatment. Toxins (Basel) 2010, 2:128-162.
42. Ulbrich H., Eriksson E.E., Lindbom L. Leukocyte and endothelial cell adhesion molecules as targets for therapeutic interventions in inflammatory disease. Trends Pharmacol. Sci. 2003, 24:640-647.
43. Wang H., Bloom O., Zhang M., Vishnubhakat J.M., Ombrellino M., Che J., Frazier A., Yang H., Ivanova S., Borovikova L., Manogue K.R., Faist E., Abraham E., Andersson J., Andersson U., Molina P.E., Abumrad N.N., Sama A., Tracey K.J. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999, 285:248-251.
44. Wolfson R.K., Chiang E.T., Garcia J.G. HMGB1 induces human lung endothelial cell cytoskeletal rearrangement and barrier disruption. Microvasc. Res. 2011, 81:189-197.
45. Wung B.S., Ni C.W., Wang D.L. ICAM-1 induction by TNFalpha and IL-6 is mediated by distinct pathways via Rac in endothelial cells. J. Biomed. Sci. 2005, 12:91-101.
46. Yang H., Ochani M., Li J., Qiang X., Tanovic M., Harris H.E., Susarla S.M., Ulloa L., Wang H., DiRaimo R., Czura C.J., Roth J., Warren H.S., Fink M.P., Fenton M.J., Andersson U., Tracey K.J. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc. Natl. Acad. Sci. USA 2004, 101:296-301.
47. Yang H., Wang H., Czura C.J., Tracey K.J. The cytokine activity of HMGB1. J. Leukoc Biol. 2005, 78:1-8.